Overview

• Researchers used large-scale gene expression data to screen over 1,300 FDA-approved drugs for potential to counter Alzheimer’s signature changes.
• Letrozole and irinotecan emerged as top candidates targeting neuronal and glial pathways disrupted in Alzheimer’s.
• In Alzheimer’s mouse models, the combination reversed brain degeneration, reduced amyloid and tau buildup, and restored memory.
• Analysis of millions of de-identified health records showed a lower incidence of Alzheimer’s among patients treated with these cancer drugs.
• Investigators plan to launch clinical trials to evaluate efficacy in patients while monitoring known side effects such as hot flashes, diarrhea, nausea and vomiting.